Hasegawa, D., & Nishida, O. (2019). Individualized recombinant human thrombomodulin (ART-123) administration in sepsis patients based on predicted phenotypes. Crit Care.
Chicago ZitierstilHasegawa, Daisuke, und Osamu Nishida. "Individualized Recombinant Human Thrombomodulin (ART-123) Administration in Sepsis Patients Based On Predicted Phenotypes." Crit Care 2019.
MLA ZitierstilHasegawa, Daisuke, und Osamu Nishida. "Individualized Recombinant Human Thrombomodulin (ART-123) Administration in Sepsis Patients Based On Predicted Phenotypes." Crit Care 2019.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.